Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

BARONE

, COLAIZZI

. Critical evaluation of thioridazine bioequivalence. Drug Intell Clin Pharm 1985: 19: 847–58.

MEYER

Jr . Comment: thioridazine bioequivalence (letter). Drug Intell Clin Pharm 1986; 20: 311.

HAMRELL

, MARTINEZ

, DIGHE

. PARKMAN PD. Bioequivalence of generic thioridazine drug products—the FDA viewpoint. Drug Intell Clin Pharm 1987; 21: 362–9.

BARONE

, COLAIZZI

. Author's reply (letter). Drug Intell Clin Pharm 1986; 20: 312.

BARONE

, COLAIZZI

. Thioridazine bioequivalence—authors’ response. Drug Intell Clin Pharm 1987; 21: 369–72.

DICKINSON

. Brands versus generics: pharmacist's role is critical. Pharm Times 1988; 54(6): 43–4.

FDA speaks out about generic drug quality.

Generics 1986; 2(July): 25–7.

STROM

. Generic drug substitution revisited. N Engl J Med 1987; 316: 1456–62.

FAICH

, MORRISON

, DUTRA

Jr , HARE

, RHEINSTFIN

. Reassurance about generic drugs. N Engl J Med 1987; 316: 1473–5.

10.

BERNER

, KATZ

. Generic drug battle: who really benefits? (letter) Wall Street Journal 1989; Oct 26: A17 col 1.

11.

WYLLIE

, PIPPENGER

, ROTHNER

. Increased seizure frequency with generic primidone. JAMA 1987; 258: 1216–7.

12.

Generics and the FDA.

Drug Topics 1989; 133(19): 5.

13.

Generic inspections expand to include anti-epileptics, drugs with narrow ranges; Dingell has “no confidence” in FDA's oversight of such products.

FDC Rep 1989; 51(40): 15–6.

14.

HEPLER

. Unresolved issues in the future of pharmacy. Am J Hasp Pharm 1988; 45: 1071–81.

15.

STRICHARCHUK

Bad medicine: drug firm's probe of the FDA threatens major agency scandal.

Wall Street Journal 1989; June 9: A1 col 1, A12 col 4.

16.

INGERSOLL

, STRICHARCHUK

Critical condition: generic-drug scandal at the FDA is linked to deregulation drive.

Wall Street Journal 1989; Sept 13: A1 col 6, A14 col 1.

17.

GROSS

. Can pharmacists, physicians, & the public trust generics? Am Druggist Sept 1989; 200(3): 25–6.

The generic drug scandal and its implications for pharmacy professionals

Abstract

Get full access to this article

References